SHANGHAI JUNSHI BIOSCIENCES
Shanghai Junshi Biosciences is a biopharmaceutical company.
SHANGHAI JUNSHI BIOSCIENCES
Industry:
Biopharma Biotechnology
Founded:
2012-01-01
Status:
Active
Contact:
86 21 5079 6193
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Domain Not Resolving Mobile Non Scaleable Content Euro ASP.NET IIS
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Shanghai Zhangjiang Yaogu Information Technology Service
Shanghai Zhangjiang Yaogu Information Technology Service is a pharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
Loyal Valley Capital
Loyal Valley Capital investment in Venture Round - Shanghai Junshi Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-07-14 | GRIT Biotechnology | Shanghai Junshi Biosciences investment in Series A - GRIT Biotechnology | N/A |
| 2021-02-09 | Zhishan Weixin Biotechnology | Shanghai Junshi Biosciences investment in Series A - Zhishan Weixin Biotechnology | N/A |
| 2021-02-02 | Coherus Biosciences | Shanghai Junshi Biosciences investment in Post-IPO Equity - Coherus Biosciences | 50 M USD |
| 2020-12-01 | IMPACT Therapeutics | Shanghai Junshi Biosciences investment in Series C - IMPACT Therapeutics | 50 M USD |
More informations about "Shanghai Junshi Biosciences"
About Us - ๅๅฎ็็ฉ
Established in 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company committed to developing first-in-class and best-in-class drugs through original innovation. With an outstanding capacity for โฆSee details»
Investors | Shanghai Junshi biosciences Co., Ltd
6 days ago With a mission of โproviding patients with world-class, trustworthy, affordable, and innovative drugs,โ Junshi Biosciences is โ In China, For Global.โ At present, the company boasts approximately 3,000 employees in the United โฆSee details»
ๅๅฎ็็ฉ
ๅๅฎ็็ฉๆ็ซไบ2012ๅนด12ๆ๏ผๆฏไธๅฎถไปฅๅๆฐไธบ้ฉฑๅจ๏ผ่ดๅไบๅๆฐ็ๆณ็ๅ็ฐใๅผๅๅๅไธๅ็็็ฉๅถ่ฏๅ ฌๅธใSee details»
Shanghai Junshi Biosciences - Crunchbase
Shanghai Junshi Biosciences may be growing as evidenced by the FDA approval of Toripalimab for advanced nasopharyngeal cancer, which marks a significant milestone in the company's โฆSee details»
Home - Junshi
Nov 24, 2022 Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency โฆSee details»
Shanghai Junshi Biosciences Co., Ltd. - Drug pipelines, Patents ...
Mar 23, 2025 Explore Shanghai Junshi Biosciences Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 244 clinical trials, 123 news, and 38 literature, Disease โฆSee details»
Shanghai Junshi Biosciences Co., Ltd. (SHJBF) Company Profile ...
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant โฆSee details»
Organization | Shanghai Junshi Bioscience Co.,Ltd.
Shanghai Junshi Bioscience Co.,Ltd. Report issue For profit Phase 1 Phase 2 Phase 3 Founded: Shanghai China (2012)See details»
Shanghai Junshi Biosciences Company Description - Stock Analysis
Mar 25, 2025 Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas โฆSee details»
Shanghai Junshi Biosciences Co Ltd: Overview - GlobalData
Shanghai Junshi Biosciences Co Ltd (Junshi Biotech) is a biopharmaceutical company that discovers, develops and commercialization of novel therapies for cancer. The company offers โฆSee details»
Shanghai Junshi Biosciences Company Profile - Craft
Oct 29, 2024 Shanghai Junshi Biosciences (ไธๆตทๅๅฏฆ็็ฉ้ซ่ฅ็งๆ) is a biopharmaceutical company dedicated to the discovery and development of drugs. Its platform technology of โฆSee details»
Shanghai Junshi Biosciences Co Ltd, 1877:HKG profile - FT.com
Mar 10, 2025 Year on year Shanghai Junshi Biosciences Co Ltd grew revenues 3.38% from 1.45bn to 1.50bn while net income improved from a loss of 2.39bn to a smaller loss of 2.28bn. โฆSee details»
Shanghai Junshi Biosciences - Investments, Portfolio & Company โฆ
Shanghai Junshi Biosciences has made 8 investments. Their most recent investment was on Nov 20, 2023 , when Ruotuo Bio raised a new funding round. How many investments has this โฆSee details»
Junshi Biosciences Announces 2024 Full Year Financial ... - BioSpace
2 days ago SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (โJunshi Biosciences,โ HKEX: 1877; SSE: 688180), a leading innovation-driven โฆSee details»
Junshi Biosciences Announces Toripalimabโs Approval in
6 days ago About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the โฆSee details»
Shanghai Junshi Biosciences Co - Company Profile - GlobalData
Shanghai Junshi Biosciences Co Ltd (Junshi Biosciences) is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, โฆSee details»
Shanghai Junshi Biosciences Co Ltd: Executives - GlobalData
The following section provides information on Shanghai Junshi Biosciences Co Ltdโs senior management, executives, CEO and key decision makers and their roles in the organization. โฆSee details»
Shanghai Junshi Biosciences Co., Ltd. | Insights
Feb 26, 2025 Latest on Shanghai Junshi Biosciences Co., Ltd. Scrip. Cancer And Blood Disorder Drugs Lead EU Novel Drug Approvals In 2024. 22 Jan 2025 โข By Neena Brizmohun. โฆSee details»
Shanghai Junshi Biosciences Enters Agreement With Eli Lilly And โฆ
May 3, 2020 May 4 (Reuters) - Shanghai Junshi Biosciences Co Ltd : Information you can trust. Reuters, the news and media division of Thomson Reuters, is the worldโs largest multimedia โฆSee details»
Junshi Biosciences Announces 2024 Full Year Financial Results and ...
5 days ago SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) โ Shanghai Junshi Biosciences Co., Ltd (โJunshi Biosciences,โ HKEX: 1877; SSE: 688180), a leading innovation-driven โฆSee details»